ArticleBritish journal of clinical pharmacology2025
Investigation of a broad-spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient-drug interactions.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Kynurenine metabolites unchanged after multinutrient supplementation in children with ADHD: a secondary data analysis from the MADDY study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Trial
- Investigation of a broad-spectrum micronutrient formulation as a possible precipitant of pharmacokinetic micronutrient-drug interactions.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsDaily broad-spectrum micronutrients are being used by the general public and formulations are receiving research interest in mental health settings. Despite concerns about combining medicines and broad-spectrum micronutrients in mental health care, there have not been any formal evaluations of potential interactions. Our objective was to evaluate a broad-spectrum micronutrient formula as a potential precipitant of pharmacokinetic drug-drug interactions through inhibition or induction of cytochrome P450 (CYP) enzymes.
methodsThis was a single-centre pharmacokinetic study. Twelve healthy participants received broad-spectrum micronutrients for 14 days (Days 1-14). Participants were administered a 'cocktail' of selective CYP probes midazolam 2 mg (CYP3A), dextromethorphan 30 mg (CYP2D6), losartan 25 mg (CYP2C9), omeprazole 20 mg (CYP2CI9) and caffeine 100 mg (CYP1A2) on Day 0 and Day 14, before taking and while taking broad-spectrum micronutrients. Plasma drug concentrations were measured at baseline and for 8 h following cocktail administration. AUC, C
resultsPre- and post-micronutrient geometric means (SD) for AUC
conclusionsBroad-spectrum micronutrients are unlikely to be a major precipitant of pharmacokinetic drug-drug interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.